Skip Navigation
  Search Menu
Find an Expert


Ronan Joseph Kelly, M.B.A., M.B.B.Ch., M.D.

Photo of Dr. Ronan Joseph Kelly, M.B.A., M.B.B.Ch., M.D.

Director of the Gastroesophageal Cancer Therapeutics Program at Johns Hopkins

Associate Professor of Oncology


Expertise: Esophageal Cancer, Gastroesophageal Cancer, Medical Oncology, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Stomach Cancer, Thymic Carcinoma, Thymoma more

Request an Appointment

I live in Maryland

Request an appointment through MyChart!

I live outside of Maryland

Request Appointment

I live outside of the United States

Request Appointment


Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 443-287-0005


Dr. Ronan Kelly, M.B.B.Ch., M.B.A is an Associate Professor of Thoracic Oncology and Director of the Gastroesophageal Cancer Therapeutics Program at Johns Hopkins. He is the co-chair of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO) taskforce on improving the quality of care received by lung cancer patients in the United States and around the World. He is an attending physician at the Johns Hopkins Hospital where he specializes in the treatment of lung cancer and gastroesophageal cancer. He also serves as the Medical Director of Global Oncology for Johns Hopkins International.

Dr. Kelly completed his medical training in 1998 from the Royal College of Surgeons in Ireland. He subsequently completed a Master's in Business Administration (MBA) from University College Dublin in 2001 where he focused on strategies to improve health care delivery efficiencies. He is a recognized expert in designing quality and value oncology metrics that will be used to measure quality of care, improve patient safety and ensure service excellence with the introduction of MACRA, alternative payment models and pathway directed treatments.    

After completing his internal medicine residency and oncology fellowship he moved to the National Cancer Institute in Bethesda MD in 2007. In 2011 he was recruited to Johns Hopkins to develop an innovative portfolio of clinical trials in lung cancer and gastroesophageal cancer. He is currently a National and International Principal Investigator on numerous phase II and phase III clinical trials investigating immunotherapeutics and novel targeted drugs in both gastroesophageal cancer and lung cancer. In addition to co-chairing the IASLC/ASCO thoracic oncology quality and value taskforce he is a member of the ASCO quality of cancer care committee, measures taskforce, and the International quality oncology practice initiative taskforce (iQOPI).  

Dr Kelly is author or co-author of more than 100 publications, including peer-reviewed journal articles, abstracts and book chapters. He has contributed his work to many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research and the Lancet.

Dr Kelly is an active member of ASCO, IASLC and ECOG (Eastern Cooperative Oncology Group). more


  • Director of the Gastroesophageal Cancer Therapeutics Program at Johns Hopkins
  • Medical Director of Global Oncology Johns Hopkins International
  • Associate Professor of Oncology



  • MB BCH BAO, Royal College of Surgeons in Ireland (1998)


  • Beaumont Hospital / Internal Medicine (2000)
  • Mater Misericordiae University Hospital / Internal Medicine (2004)


  • Waterford Regional Hospital / Medical Oncology (2005)
  • Beaumont Hospital / Medical Oncology (2006)
  • Tallaght Hospital / AMNCH / Medical Oncology (2007)
  • National Cancer Institute-Oncology / Medical Oncology (2011)

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 


Is this you? Edit Profile